Drug Search Results
More Filters [+]

Nalbuphine

Alternative Names: nalbuphine, nubain, Naldebain, Haduvio
Latest Update: 2024-07-08
Latest Update Note: Clinical Trial Update

Product Description

Nalbuphine is FDA indicated for moderate to severe pain in which an opioid agent is required when other alternative treatments have been insufficient. Non-FDA approved uses of nalbuphine do exist, such as treatment of labor pain, opioid-induced urinary retention, opioid-induced respiratory depression, and pruritus associated with neuraxial opioid use.

Mechanisms of Action: OPRM Antagonist,OPRK Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Korea | Lebanon | Malaysia | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Singapore | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Ukraine | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Trevi
Company Location: NEW HAVEN CT 06510
Company CEO: Jennifer L. Good
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nalbuphine

Countries in Clinic: Australia, Austria, Canada, Chile, France, Germany, Italy, Netherlands, Poland, Spain, Taiwan, Turkey, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Prurigo|Pruritus

Phase 2: Idiopathic Pulmonary Fibrosis|Pain, Postoperative|Refractory Chronic Cough|Unexplained Chronic Cough

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NAL03-202

P2

Recruiting

Idiopathic Pulmonary Fibrosis

2024-12-31

Oral SDE+AAP-001

P2

Enrolling by invitation

Pain, Postoperative

2024-12-31

32%

Oral SDE+AAP-001

P2

Enrolling by invitation

Pain, Postoperative

2024-12-31

32%

CORAL

P2

Recruiting

Idiopathic Pulmonary Fibrosis

2024-10-01

RIVER

P2

Recruiting

Refractory Chronic Cough|Unexplained Chronic Cough

2024-09-01

35%

Recent News Events